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Vascular endothelial growth factor A (VEGF) is highly
expressed in adipose tissue. Its role, however, has
not been fully elucidated. Here, we reveal the meta-
bolic role of adipose-VEGF by studying mice with
deletion (VEGFAdD) or doxycycline-inducible over-
expression of a VEGF transgene (VEGFAdTg) in the
adipose tissue. VEGFAdDmice have reduced adipose
vascular density and show adipose hypoxia, apo-
ptosis, inflammation, and metabolic defects on a
high-fat diet. In contrast, induction of VEGF expres-
sion in VEGFAdTg mice leads to increased adipose
vasculature and reduced hypoxia. The latter changes
are sufficient to counteract an established compro-
mising effect of high-fat diet on the metabolism,
indicating that metabolic misbalance is reversible
by adipose vessel density increase. Our data clearly
show the essential role of VEGF signaling for ade-
quate adipose function. Besides revealing insights
into the molecular mechanisms of obesity-related
metabolic diseases, this study points to the thera-
peutic potential of increased adipose angiogenesis.
INTRODUCTION
Obesity, defined as an excess of whole-body adipose tissue,
has become a global health problem and a leading cause of
several chronic illnesses, including type 2 diabetes (WHO,
2010; Yach et al., 2006). There is increasing evidence that
adipose tissue does not simply store energy but is also an
essential endocrine organ, producing hormones and secreting
growth factors and chemokines (Waki and Tontonoz, 2007),
commonly termed adipokines. These molecules are crucial forCboth local and systemic communication between adipose and
other tissues.
The connection between obesity and metabolic diseases is
well established, and increasing efforts are taken to unveil the
mechanisms underlying this association. Obesity is accompa-
nied by major changes in the properties of the adipose tissue,
including elevated expression of proinflammatory markers,
such as CRP, IL-6, TNFa, MCP-1, and MIF (Hotamisligil, 2006;
Wellen and Hotamisligil, 2005). These inflammatory factors
are major contributors to the metabolic disease phenotype
(Weisberg et al., 2003; Xu et al., 2003). On the other hand, adipo-
nectin, a hormone produced exclusively by adipose tissue, plays
a positive modulatory role in glucose regulation and suppression
of the metabolic syndrome and type 2 diabetes (Yamauchi et al.,
2001, 2002).
Adipose tissue is characterized by its ability for lifelong growth
and almost unlimited expansion. As in other tissues, fat expan-
sion requires concomitant neovascularization to enable delivery
of oxygen and nutrients (Cao, 2007; Christiaens and Lijnen,
2010; Hausman and Richardson, 2004; Lijnen, 2008). To pro-
mote neovascularization during its expansion, adipose tissue
expresses various angiogenic growth factors, such as vascular
endothelial growth factor (VEGF), fibroblast growth factor
(FGF), placental growth factor (PlGF), and leptin (Cao, 2007;
Lijnen et al., 2006; Miyazawa-Hoshimoto et al., 2003).
Similar to tumor neovascularization (Kerbel, 2008), the critical
role of adipose vasculature in tissue growth has generated much
interest. Efforts have been made to utilize inhibition of angiogen-
esis as a potential therapeutic approach for the treatment of
obesity and/or diabetes. Indeed, a number of systemically
applied angiogenesis inhibitors have shown preliminary efficacy
and promise in preclinical models of obesity and metabolic
dysfunction (Bra˚kenhielm et al., 2004; Cao, 2010; Liu et al.,
2010; Rupnick et al., 2002). Several hypotheses have been
proposed to explain the inflammatory response of adipose tissue
to pathologic expansion, including oxidative stress (Houstisell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc. 61
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sligil, 2007; Ozcan et al., 2004), and hypoxia (Hosogai et al.,
2007; Trayhurn et al., 2008). Although these possible mecha-
nisms could be interrelated, hypoxia is likely to play key causal
roles in adipocyte dysfunction and the development of insulin
resistance (Chi et al., 2006; Goossens et al., 2011; Hosogai
et al., 2007; Pasarica et al., 2009, 2010; Wood et al., 2009; Tray-
hurn et al., 2008; Yin et al., 2009) by inducing inflammation,
which in turn leads to massive changes in adipokine profiles
and ectopic lipid deposition in insulin sensitive organs. Hypoxia
in the adipose tissues of ob/ob and diet-induced obese (DIO)
mice has been linked to inadequate angiogenesis (Hosogai
et al., 2007; Yin et al., 2009), which could point to insufficient
adipose VEGF signaling as the initiating element of a cascade
of events that leads to metabolic diseases.
To shed further light on these events, we developed two kinds
of genetically modified mice in which adipose-specific blood
vessel density is modulated: adipose-specific deletion of VEGF
(VEGFAdD), and doxycycline-inducible overexpression of VEGF
(VEGFAdTg). Importantly, the specificity of deletion and transgene
overexpression is identical. We show that mice selectively defi-
cient for adipose VEGF develop an abnormally sparse adipose
vascular network. The decreased vessel density has dramatic
negative effects on the metabolic phenotype of these animals.
Conversely, adipose-specific expression of VEGF not only
protects mice from development of metabolic abnormalities
(Hagberg et al., 2010; Liu et al., 2010) but also improves already
compromised metabolic functions brought on by a high-fat diet.
These findings strongly support our hypothesis that insufficient
adipose VEGF signaling initiates a cascade of events that ends
with metabolic disease. Furthermore, they show that restoring
adequate vessel density in metabolically challenged obese indi-
viduals reverts the disease. The latter opens up a new avenue for
novel therapeutic approaches.
RESULTS
Adipose-Specific Ablation of VEGF Results in Reduced
Vascular Density and Growth of Adipose Tissue
Adipocytes and resident macrophages are the major sources of
VEGF in adipose tissues (Cho et al., 2007; Mick et al., 2002;
Zhang et al., 1997). We knocked out VEGF specifically in these
two cell types to determine its effect on adipose blood vessel
development. We then crossed mice bearing a Cre recombi-
nase-conditional VEGF allele (VEGFloxP) (Gerber et al., 1999)
with those harboring an aP2-Cre recombinase transgene (see
Figure S1A online). The latter is very well characterized and
known to restrict expression to adipocytes and macrophages
(He et al., 2003). Mice with the genotypes marked as ‘‘control’’
in Figure S1A were phenotypically indistinguishable from wild-
type mice (data not shown).
Adipose tissue-specific VEGF knockout mice (aP2-Cre(+);
VEGF(loxP,loxP), hereafter referred to as VEGFAdD) were born at
the expected Mendelian ratio, were viable and fertile, and
showed no gross abnormalities (data not shown). Only trace
amounts of mRNA and VEGF protein were detected in their white
(WAT) and brown (BAT) adipose tissues by quantitative PCR and
western blot, respectively (Figures 1A and 1B). In contrast, the
VEGF mRNA levels in other tissues, such as muscle and liver,62 Cell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc.and the serum level of VEGF were similar to those of controls
(Figures 1A and 1C), confirming the adipose-specific loss of
VEGF. The gross appearance of WAT from VEGFAdD mice was
pale compared to that of the controls (Figure 1D, panel Gross),
suggesting reduced blood perfusion. When blood vessels were
visualized by whole-mount immunostaining using a PECAM-1
antibody, it was evident that the vascular densities of both
WAT and BAT in VEGFAdD mice were significantly lower than in
the control (Figures 1D [panels PECAM-1], Figures 1E and 1F).
To rule out the possibility of an autocrine effect of VEGFmodu-
lation on adipocyte function, we studied two gene-targeted
mouse lines with lacZ knocked into the loci for either the Flk1
(Ema et al., 2006) or the Flt1 (Fong et al., 1995) VEGF receptors.
X-gal-stained WAT and BAT from these mice revealed that the
receptors were expressed by endothelial cells (Figure S1B,
yellow arrowheads), but not by white or brown adipocytes (Fig-
ure S1B, red arrows). We therefore conclude that the effect of
VEGF on adipose function is manifested in a paracrine manner
through blood vessels.
Given the critical importance of adequate angiogenesis for
tissue growth, we inferred that reduced adipose vascularization
in VEGFAdD mice may hinder fat tissue expansion and, conse-
quently, body weight gain. Consistent with this expectation,
the juvenile body weight of these animals was slightly lower
than that of controls (Figure 1G). Magnetic resonance-assisted
measurements of body composition revealed a significant
reduction in their fat mass, while their leanmass remained similar
to controls (Figure 1H). Subsequent weight measurements of fat
tissues harvested from these mice showed that the reduction in
fat weight was more prominent in perigonadal (PGF) than in
subcutaneous fat (SCF) (Figure 1I). Since Cre-recombinase
activity level is identical in these two tissues (data not shown),
these findings indicate a higher sensitivity of perigonadal fat to
adipose VEGF deletion than that of subcutaneous fat. The adipo-
cyte size in WAT and weight of the BAT in the VEGFAdDmice was
not significantly different from those of controls (data not shown).
Furthermore, histological examination of the liver and skeletal
muscle did not reveal any difference between experimental
groups (data not shown). In summary, the above studies showed
that adipose VEGF ablation decreased fat tissue vascularity with
a concurrent fat mass reduction in WAT.
Altered Adipokine Expression in the WAT of VEGFAdD
Mice
Next, we investigated the changes in metabolic parameters and
the gene expression level on a panel of thermo- and lipogenic
genes in 12- to 16-week-old VEGFAdD animals. The reduced
vascularization (Figure 1D, middle panel, and Figure 1E) was
accompanied by a significantly reduced population of endothe-
lial cells in the WAT, indicated by a decreased level of VEGFR-2
in this tissue (Flk1; Figure 1J). We found no differences in food
consumption (Figure S1C), serum triglyceride (TG) (data not
shown), or fasting glucose levels, or in intraperitoneal glucose
tolerance tests (Figure S1D). Furthermore, similar serum insulin
levels (data not shown) indicated a normal glucose homeostasis
in VEGFAdD animals. While mRNA levels of most adipogenic or
adipose secreted factors were unchanged (Figure S1E), the
expression of adiponectin, an antidiabetic adipokine, was
significantly reduced (Figure 1K), and expression of TNF-a,
Figure 1. Phenotypic Consequences of
VEGF Ablation in the Adipose Tissues of
Animals Maintained on Standard Chow
(A) Quantitative PCR analysis for VEGF gene
expression in white and brown adipose tissue
(WAT and BAT, respectively), liver, and skeletal
muscle (n = 4 for both groups).
(B) Western blotting analysis for tissue VEGF
protein in WAT.
(C) Serum VEGF concentration determined by
ELISA (n = 6 for control, n = 10 for VEGFAdD).
(D) Upper panel, gross appearance of WAT.
Middle and lower panels, confocal microscopic
image of whole-mount WAT and cryosectioned
BAT immunostained with PECAM-1 antibody to
show vessel density.
(E and F) Quantification of vessel densities of both
WAT (E) and BAT (F) by intensity of the immuno-
fluorescent signal (WAT, n = 5 for control, n = 7 for
VEGFAdD; BAT, n = 4 for both).
(G) Body weight changes with age (n = 10–15 for
control, n = 6–16 for VEGFAdD).
(H) Magnetic resonance-assisted determination of
percent fat and lean mass (n = 6 for both groups).
(I–L) (I) Fat weight (n = 5 for both groups). qPCR
analysis of Flk-1 (J), Adiponectin (K), and Tnfa (L)
expression in WAT (n = 3–4 for both groups).
(M) Serum-free fatty acid level at fasting and 3 hr
after oil gavage (n = 7 for both groups).
All data are presented as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.005. Scale bars, 0.5 cm in (D)
upper panel and 100 mm in all microscopic images.
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ures 1L). Fasting free fatty acid (FFA) in the serum was the
same as in the control. Oral lipid challenge, however, dramati-
cally increased FFA in VEGFAdD animals, indicating a defective
lipid handling capability (Figure 1M).
Interestingly, some of the thermo- and lipogenic gene ex-
pression levels were lower in the BAT of the VEGFAdD animals
(Figure S1F), but this decrease did not affect the energy expen-
diture and ambulatory activity (Figures S1G and S1H) of the
animals.Cell Metabolism 17, 61–VEGFAdD Mice Develop Metabolic
Defects and Insulin Resistance on
a High-Fat Diet
Although VEGFAdD animals were slightly
leaner than the controls, they developed
a mild metabolic impairment when kept
on standard chow (SC). This finding
prompted us to challenge these animals
with a high-fat diet (HFD, 60% of calories
from fat), expecting an accelerated
development of their metabolic disease.
We based this expectation on the obser-
vation of increased adipose VEGF
expression on HFD both in normal (Fig-
ure S2A) and in ob/ob mice (Halberg
et al., 2009). From 12 weeks of age, the
experimental and control mice were
kept on HFD, and their body weightswere monitored. During the first 3 weeks, the VEGFAdD animals
showed only a slightly lower weight gain than controls; however,
over time, a wider difference (Figure 2A) and less fat mass devel-
opment became apparent in these animals (Figure 2B), while the
size of the adipocytes remained comparable (Figure S2B).
Freshly harvested WAT from VEGFAdD animals were darker
than that of the controls (Figure 2C, panel Gross), and histolog-
ical examination revealed high levels of inflammatory cell
infiltration into the VEGF-deficient tissues (Figure 2C, panel
WAT [H&E]).72, January 8, 2013 ª2013 Elsevier Inc. 63
Figure 2. Metabolic Consequences of Ablation of VEGF in Adipose Tissue in Animals Kept on High-Fat Diet
(A) Body weight changes of experimental animals during HFD feeding (n = 9 for control, n = 6 for VEGFAdD).
(B) WAT (Perigonadal fat, PGF) weight measurement after 18 weeks of HFD feeding (n = 6 for both groups).
(C) Histopathological changes in VEGFAdD mice after HFD. (Gross), gross appearance of WAT; WAT (H&E), hematoxylin and eosin staining of WAT; BAT (H&E),
hematoxylin and eosin staining of brown adipose tissue; Liver (toluidine), toluidine blue staining of semithin sectioned liver tissue. Black arrowheads indicate
localization of cytoplasmic vacuoles in hepatocytes in VEGFAdD mice. Liver (TEM), transmission electron microscopic examination of liver of HFD-fed animals.
Arrowheads indicate cytoplasmic vacuolation in hepatocytes.
(D–F) (D) Liver triglyceride (TG), (E) serum measurement of fasting cholesterol, and (F) serum-free fatty acid concentrations (n = 5–9 for both groups).
(G) Insulin (ITT) and (H) glucose tolerance test (IPGTT) after HFD (n = 13 for control, n = 11 for VEGFAdD).
All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. Scale bars, 0.5 cm in (C) upper panel and 100 mm in all microscopic images.
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bled a white adipocyte-like unilocular, rather than a typical multi-
locular, morphology (Figure 2C, panel BAT [H&E]). In the livers of
VEGFAdD animals, numerous cytoplasmic vacuoles were local-
ized around the portal veins (data not shown) and were present
in the hepatocytes close to the hepatic sinusoidal endothelium
(Figure 2C, panel Liver [toluidine] and panel Liver [TEM]). The
electron density of these vacuoles was comparable to that of
the lipid droplets in adipocytes (data not shown), which was
consistent with the increased liver triglyceride level of the
VEGFAdD animals (Figure 2D). Thus the pathological manifesta-
tion of a HFD challenge was presented in both white and brown
adipose tissue, as well as in the hepatocytes of the VEGFAdD
mice, implying that these animals may have global defects in
their metabolic homeostasis.
Although there were no differences in fasting blood glucose
levels and in expression of Fabp4 and VEGF in liver and muscle
(Figures S2C and S2D) after 18 weeks on HFD, the VEGFAdD
animals showed significantly elevated total cholesterol (Fig-
ure 2E) and decreased fasting level of FFA levels in the serum64 Cell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc.(Figure 2F). More importantly, the VEGFAdD animals developed
severe insulin resistance (Figure 2G) and glucose intolerance
(Figure 2H).
VEGFAdD Animals on a High-Fat Diet Show Increased
Macrophage Infiltration, Adipocyte Apoptosis, and
Inflammation of White Adipose Tissues
Immunohistochemical staining with an F4/80 antibody proved
the macrophage origin of the inflammatory cells infiltrating the
adipose tissue in HFD-fed VEGFAdD animals (Figures 3A and
3B). The macrophages were highly concentrated (Figures 3C
and 3E) in areas with low or no perilipin signal (Figures 3C and
3D), possibly marking the location of apoptotic adipocytes
where macrophages are performing their scavenging function
(Cinti et al., 2005; Strissel et al., 2007). Elevated numbers of
active caspase-3-positive cells in VEGFAdD adipose tissue
further supported this finding (Figures 3F and 3G).
Consistent with these observations, expression of inflamma-
tory genes such as plasminogen activator inhibitor-1 (PAI-1),
TNF-a, and macrophage chemotactic factor-1 (MCP-1) were
Figure 3. Properties of the Adipose Tissue of VEGFAdD Animals Kept on High-Fat Diet
(A) F4/80 immunohistochemistry detecting murine macrophage infiltration in WAT.
(B) Quantification of F4/80-positive cell numbers per field (n = 6 for both groups).
(C) Whole-mount WAT double stained with perilipin (adipocyte, green) and F4/80 (macrophage, red) antibodies.
(D and E) Percent area of (D) perilipin-low and (E) F4/80-positive regions (n = 6 for control, n = 5 for VEGFAdD).
(F and G) (F) Immunofluorescent staining of whole-mount WAT with caspase-3 antibody and (G) its quantification (n = 6 for both groups).
(H) Gene expression analysis by qPCR (n = 5–9 per each group).
All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. Scale bars, 100 mm in all microscopic images.
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were significantly decreased (Figure 3H) in these mice. On the
other hand, we did not find significant changes in apoptotic
cell numbers and inflammatory cell infiltration in the BAT of
VEGFAdD animals (data not shown) kept on HFD. Although we
found decreased expression of some lipogenic genes in the
BAT (Figure S3A), this did not result in any significant differences
in energy expenditure or in total activity level (Figures S3B
and S3C).
Since the adipose tissue in VEGFAdD mice was poorly vascu-
larized, we investigated whether hypoxia could be part of the
mechanism leading to adipocyte apoptosis. We detected signif-
icantly reduced vascular perfusion in the WAT of the VEGFAdD
animals (Figures 4A and 4B). Consistent with this phenotype,
the visualization of hypoxic areas by pimonidazole immunostain-
ing of whole-mount adipose tissue revealed a 3-fold increase in
hypoxic areas in VEGFAdD mice compared to controls (Figures
4C and 4D). We also compared the degree of hypoxia under
different dietary conditions (Figure S4). Similar to findings in
earlier studies (Hosogai et al., 2007), HFD resulted in increasedCadipose hypoxia compared to SC. The effect of HFD on adipose
hypoxia was much more pronounced in VEGFAdD mice than in
control animals (Figure S4).
Our results suggest that hypoxia is associated with adipocyte
apoptosis and macrophage infiltration. This inflammation in the
adipose tissue leads to abnormal production of adipokines and
ectopic lipid depositions, to the known cause of glucose in-
tolerance and insulin resistance (Virtue and Vidal-Puig, 2010;
Weisberg et al., 2003; Xu et al., 2003).
Taken together, these data indicate that adipose VEGF is
critical for maintaining the viability and metabolic/endocrine
function of adipocytes through its role in regulating adequate
vascularization and blood perfusion.
Generation and Characterization of Adipose-Specific
Inducible VEGF164-Overexpressing Genetic Model
Our loss-of-function studies clearly showed the critical role of
adipose VEGF and vessel density and suggested that hypoxia
might be the cause for adipose dysfunction. We therefore ex-
pected that experimentally increased blood vessel density inell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc. 65
Figure 4. Consequences of Adipose Tissue
Hypoperfusion in VEGFAdD Mice
Ultrasonic detection ofWAT tissue perfusion using
time course wash in of IV-injected microbubbles.
(A) Color-contrasted image of injected micro-
bubble.
(B) Quantification of bubble (green signal inside
dotted line of A) intensity (n = 6 for control, n = 5 for
VEGFAdD).
(C) Immunofluorescent staining of whole-mount
WAT with pimonidazole and PECAM-1 antibodies
to detect hypoxia and vessel density, respectively.
Negative control, no primary antibody.
(D) Morphometric quantification of immunofluo-
rescent signal in pimonidazole positive areas (n = 5
for control, n = 4 for VEGFAdD).
All data are presented as mean ± SEM. **p < 0.01,
***p < 0.005. Scale bars, 100 mm in all microscopic
images.
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induced metabolic defects to a normal state. To this end, we
crossed three well-characterized transgenic mouse lines: mice
carrying a Cre recombinase conditional rtTA knockin into the
Rosa26 locus (Belteki et al., 2005), a tet-O-VEGF164 (Akeson
et al., 2003), and an aP2-Cre transgene (He et al., 2003). Triple
transgenic animals (Figure 5A, designated VEGFAdTg) were ex-
pected to overexpress VEGF164 exclusively in adipocytes and
macrophages in a doxycycline (DOX)-inducible manner with
the same specificity as the VEGF deletion in our loss-of-function
model.
The appearance of the adipose tissue, blood vessel density,
and adipocyte size in noninduced VEGFAdTg mice was similar
to that of controls, indicating that the transgene is silent in the
absence of DOX (data not shown). To avoid possible negative
effects (such as increased vascular permeability) of continuous
VEGF164 induction (Ozawa et al., 2004), we applied ametronom-
ically alternating DOX-on and DOX-off treatment regime consist-
ing of a 4 day feeding period with SC followed by a 3 day feeding
with doxycycline-containing SC (Standard/DOX diet regime, Fig-
ure 5B). After two cycles of this diet regime, freshly harvested
WAT of DOX-treated VEGFAdTg animals appeared more vascu-
larized compared to control mice (single or double transgenic66 Cell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc.littermates; Figure 5C, upper panels).
Whole-mount immunostaining with a
PECAM-1 antibody revealed increased
vascular density (Figures 5C, lower
panels; Figure 5D) with numerous sprout-
ing vascular tip cells, indicating that
VEGF164 transgene induction resulted
in active angiogenic processes in the
adipose tissue of DOX-treated VEGFAdTg
animals (Figure 5C, lower panel, inset).
There were no significant differences in
body weight gain or food consumption
between the two groups (Figure 5E and
Figure S5A) during the observed period.
Furthermore, we did not find any differ-
ence in random serum glucose levels(Figure 5F), intraperitoneal glucose tolerance, or insulin tolerance
(Figures S5B and S5C).
We continued to characterize our adipose-specific inducible
VEGF transgenic system in animals on HFD challenge. First we
tested if we could recapitulate a recently published finding (Elias
et al., 2012; Sun et al., 2012) that VEGF activation in adipose
tissue at the time of HFD exposure protects animals from meta-
bolic disease development. Similarly to the characterization on
SC, here we applied the metronomic alternation of DOX-on
and DOX-off treatment regime consisting of a 4 day feeding
period with normal HFD followed by 3 day feeding with doxycy-
cline containing high-fat chow (HFD/DOX diet regime) (Fig-
ure S6A). Four days after the start of the HFD feeding, we acti-
vated VEGF expression in the VEGFAdTg animals using seven
cycles of the HFD/DOX diet regime. The treatment resulted in
a significant increase in VEGF164 expression both in WAT and
in BAT, but not in the liver (Figure S6B). There was no difference
in food intake, body weight gain, fat composition, fasting blood
glucose levels, serum FFA, TG, total cholesterol, or glucose
tolerance (data not shown) between the groups. However,
while the control animals developed insulin resistance and
hyperinsulinemia, the VEGF164-induced animals were pro-
tected from these (Figures S6C and S6D). Consistent with our
Figure 5. Generation and Basic Characteristics of Adipose-Specific Inducible VEGF164-Expressing Genetic Mouse Model
(A) Generation of adipose-specific and doxycycline-inducible VEGF164 triple transgenic mice (VEGFAdTg).
(B) Schematics of metronomic induction of VEGF164 with standard chow (SC) and doxycycline-containing chow (DOX) (Standard/DOX diet regime).
(C) Gross appearance (upper panel) and PECAM-1 staining (lower panel) of WAT after two cycles of SC/DOX diet regime.
(D) Body weight changes during ten cycles of SC/DOX diet regime (n = 8 for control, n = 6 for VEGFAdTg).
(E) Fasting blood glucose level after ten cycles of Standard/DOX diet regime (n = 7 for both groups).
All data are presented as mean ± SEM. *p < 0.05. Scale bars, 0.5 cm in (C) upper panel and 100 mm in all microscopic images.
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increased inflammatory cell infiltration (Figure S6E, panel WAT,
arrowheads). We also observed elevated lipid deposition in the
BAT and liver (Figure S6E, panel BAT [H&E] and Liver [H&E])
and enlarged islet cell mass (Figure S6E, panel Pan [H&E]).
Therefore, we concluded that when VEGF induction and HFD
challenge were applied simultaneously, aP2-specific induction
VEGF protects animals from HFD-induced metabolic defect
and insulin resistance. We then attempted to identify the mech-
anism underlying the protective effect of VEGF in thesemice and
investigated whether it was mediated through the modulation of
adipose vessel density and hypoxia. Whole-mount PECAM-1
staining showed an increased vascular network in the adipose
tissue of the DOX-induced VEGFAdTg animals (Figure S6F, panel
PECAM-1), resulting in increased tissue perfusion compared to
that of the controls (Figure S6F, panel Microbubble). Consistent
with these observations, hypoxia was significantly decreased in
the WAT of VEGFAdTg mice (Figure S6F, panel Pimonidazole),
which was accompanied by higher expression of adiponectin
and PPARg and lower expression inflammatory cytokine TNF-a
(Figure S6G). The level of circulating adiponectin was also signif-
icantly higher in VEGFAdTg animals (Figure S6H). Decreased
hypoxia was associated with a lower level of caspase-3 expres-
sion (Figure S6G), reduced caspase-3-positive cell numberC(Figures S6I and S6J), and inflammatory cell infiltration in the
adipose tissue of VEGFAdTg mice compared with controls (Fig-
ure S6E, panel WAT). Although adipocyte size was reduced,
we did not detect significant differences in blood vessel density
or thermo- and lipogenic gene expression pattern in the BAT and
energy expenditure of two groups (Figures S6K–S6M),
suggesting a moderate effect of VEGF164 on morphological
and functional changes in BAT.
Transgenic Expression of VEGF164 Reverts High-Fat-
Diet-Induced Glucose Intolerance
We then asked if VEGF activation in the adipose could revert an
already established metabolic disease induced by HFD. First we
challenged the VEGFAdTg (and controls animals) with HFD in the
lack of doxycycline for 8 weeks. Then we applied four cycles of
metronomic treatment of HFD/DOX diet regime (Figure 6A). The
animal’s body weight and glucose tolerance were monitored at
Start and Term as well as weekly during the study (Figures 6B
and 6C). After 8 weeks of HFD feeding (at Start), glucose clear-
ance was delayed in both groups—reflected by high AUC
values—indicating their glucose intolerant status (Figure 6C, at
Start). After four metronomic cycles of the HFD/DOX diet (at
Term), we found a surprising reversal effect on glucose intoler-
ance accompanied with dramatic reduction in body weight andell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc. 67
Figure 6. Metronomic Induction of VEGF164 Expression Improves Glucose Tolerance in Diet-Induced Obese Mice
(A) Schematics of metronomic induction of VEGF164 with high-fat diet (HFD) and doxycycline-containing HFD (HFD/DOX regime). HFD was given for 8 weeks
followed by metronomic 3 days of DOX ON and 4 days of DOX OFF cycle as indicated in control and VEGFAdTg mice.
(B) Body weight was monitored during the HFD/DOX treatment (represented as a percent of initial body weight) (n = 6–8 per each group).
(C) Left panel, intraperitoneal glucose tolerance test (IPGTT) at starting point of HFD/DOX regime (0 weeks) and its area under the curve (AUC). Right panel, IPGTT
at 4 weeks after HFD/DOX metronomic treatment and its AUC (n = 6–8 per each group).
(D) Histopathological changes in control and VEGFAdTg mice after 4 weeks of HFD/DOX regime. WAT (H&E), hematoxylin and eosin staining of WAT; BAT (H&E),
hematoxylin and eosin staining of brown adipose tissue; Liver (H&E), hematoxylin and eosin staining of liver tissue; Pancreas (H&E), Liver (H&E), hematoxylin and
eosin staining of pancreas. All data are presented as mean ± SEM. Scale bars, 25 mm in WAT and BAT, and 50 mm in liver and pancreas.
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Besides the known, general glucose lowering effect of Dox treat-
ment (Basaria et al., 2002; Garbitelli, 1987; Odeh and Oliven,
2000), our treated VEGFAdTg animals showed improved glucose
tolerance compared to the controls (Figure 6C, Term). This result
is the first testament that a diagnosed metabolic disease is
reversed by induced expression of adipose VEGF.
These data prompted us to challenge the 8 week HFD-
exposed VEGFAdTg mice with more aggressive DOX treatment
and then a longer no-DOX time (Figure 7A). At Start we exposed
animals to DOX for 2 weeks followed by 2 weeks of no DOX. At
the start of the doxycycline treatment, the groups did not differ in
their body weight, food consumption, or glucose tolerance
(Figures 7B and 7C, Figures S7A and S7B). Similarly to the
previous experiment, the high AUC indicated that glucose intol-
erance developed in both groups (Figure 7C, left panel). After
feeding with HFD+DOX for 2 weeks, VEGFAdTg mice showed
a significant reduction in total body weight (Figure 7B), mostly
due to the reduction of fat mass (Figure S7C). Most importantly,
thesemice showed significant improvement in glucose tolerance
(Figure 7C, middle panel, and Figure S7D, middle panel DOX
ENDs), while their circulating adiponectin was increased (Fig-
ure S7E). This improvement, however, was found to be VEGF
induction dependent; the metabolic compromise rapidly re-
established 2 weeks after the doxycycline treatment was
stopped (Figure 7C, right panel, and Figure S7D, right panel).68 Cell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc.We then evaluated whether increased vascular densities, and
the resulting decrease in tissue hypoxia and inflammation, could
be the possible mechanisms for the metabolic improvement in
these animals. Indeed, we could observe reduced adipocyte
size (Figure 7D, upper panels), increased vascular density (Fig-
ure 7D,middle panels), and reduced adipose hypoxia (Figure 7D,
bottom panels) in VEGFAdTg mice. Moreover, inflammatory
CD11b and F4/80 double positive macrophage infiltration was
also reduced in these animals (Figures 7E and 7F), which could
further contribute to their metabolic improvement. There was
no difference between the groups in food intake, rectal body
temperature, fecal lipid content, energy expenditure, or serum
lipid (FFA and TG) at Start and Term of the HFD/DOX regime
(data not shown).
In summary, these data strongly suggested that adipose-
specific VEGF164 expression could reverse metabolic anoma-
lies. This reversal is mediated by suppression of hypoxia, inflam-
mation, and apoptosis in theWAT. This leads to the restoration of
normal secretion of adipokines and the inhibition of lipid accu-
mulation in insulin-sensitive nonadipose tissues, and therefore
improved metabolic homeostasis.
DISCUSSION
The development of obesity-related pathologic conditions, such
as fatty liver, cardiovascular diseases, and type 2 diabetes, has
Figure 7. Induction of VEGF164 Reverts
Glucose Intolerance in High-Fat-Diet-
Induced Obese VEGFAdTg Mice
(A) Schematics of VEGF164 induction and with-
drawal. HFD was given for 8 weeks followed by
metronomic 2 weeks of DOX ON (VEGF164
induction) and 2 weeks of DOX OFF (VEGF164
withdrawal) in control and VEGFAdTg mice (n = 8 for
control and n = 7 for VEGFAdTg mice).
(B) Body weight change during the DOX treatment
regime in control and VEGFAdTg mice (n = 8 for
control and n = 7 for VEGFAdTg mice; *p < 0.05).
(C) IPGTT in control and VEGFAdTg mice at start
(right panel, 0 weeks), 2 weeks after DOX (middle
panel, 2wk DOX[+]) and 2 weeks after DOX with-
drawal (right panel, 2wk DOX[]) (n = 8 for control
and n = 7 for VEGFAdTg mice).
(D) Whole-mount immunostaining of adipose
tissue from HFD-fed control and VEGFAdTg mice.
Top panel, perilipin staining and adipocyte diam-
eter. Middle panel, PECAM-1 staining and its
quantitation. Bottom panel, hypoxyprobe staining
and its quantitation.
(E and F) Whole-mount immunostaining (E) and
flow cytometry analysis (F) of macrophage in the
adipose and its quantitation (n = 3–4 for both
groups). All data are presented as mean ± SEM.
*p < 0.05, **p < 0.01.
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status, lifestyle, and complex genetic factors. Mouse models
have been used intensively to study the mechanisms behind
the pathogenesis of these diseases (Hosogai et al., 2007; Yin
et al., 2009). Hypoxia due to insufficient vascularization of the
adipose tissue has been suggested as one important contrib-
uting factor (Hosogai et al., 2007). Recent human studies have
confirmed that low vascular density in adipose tissues is directly
associated with an abnormal metabolic profile (Pasarica et al.,
2009, 2010). Obese patients often show decreased circulation
and reduced perfusion rates in adipose tissues, which suggests
that adipose hypoxiamay play a role in the development ofmeta-
bolic defects (Pasarica et al., 2009, 2010). These studies
propose that adipose tissue hypoxia might be a link between
obesity and its metabolic consequences. However, it is not clear
whether hypoxia is a cause or a consequence of obesity-related
metabolic disease.
VEGF is the key regulator of angiogenesis (Carmeliet, 2003;
Folkman, 1995). In a variety of tissues, changes in VEGF activity
positively correlate with microvascular density and hence bloodCell Metabolism 17, 61–perfusion, which governs the oxygena-
tion of tissues (Baffert et al., 2006; Kamba
et al., 2006). In adipose tissue, VEGF
expression is differentially regulated de-
pending on the anatomical locations of
the fat depot and dysregulated in obese
individuals (Cao, 2007; Goossens et al.,
2011; Halberg et al., 2009; Liu et al.,
2010; Miyazawa-Hoshimoto et al., 2005;
Pasarica et al., 2009). To alter tissue per-
fusion via modulation of adipose blood
vessel density, we employed geneticallyengineered mouse models to generate VEGF deficiency (i.e.,
loss of function, LOF) or doxycycline-inducible overexpression
(i.e., gain of function, GOF) restricted to the adipose tissue. In
both cases, the well-characterized aP2-Cre transgenic mice
(He et al., 2003) provided the desired specificity. The aP2
promoter is active in white and brown adipocytes as well as
macrophages (Fu et al., 2000; Furuhashi et al., 2008; Makowski
et al., 2001), rendering it ideally suited to generate adipose-
specific VEGF alterations. Although the adipose specificity of
the aP2-Cre transgene is well characterized, there are reports
indicating that a HFD could induce ectopic aP2 expression in
other metabolically important organs (Segal et al., 1992). There-
fore, we evaluated the expression of Fabp4 (aP2) and VEGF
levels in the liver and muscles. We did not detect any changes
in these tissues (Figure S2D), which ruled out the possibility
that other organs played direct VEGF level-dependent roles in
the development of the VEGFAdD and VEGFAdTg phenotypes.
Young animals challenged with a HFD developed severe
hypoxia, adipocyte apoptosis, and inflammation, which eventu-
ally led to insulin resistance. The associated lipid accumulation in72, January 8, 2013 ª2013 Elsevier Inc. 69
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network in adipose tissue is a critical determinant for adipose
lipid storage capacity. When the low vessel density-determined
storage capacity of the adipose tissue was surpassed, lipid
was deposited into ectopic sites including brown fat, liver,
and muscle. The ectopic fat is likely to cause lipotoxicity in
the liver and muscles, contributing to the development of
insulin resistance (Kim et al., 2007; Savage, 2009; Virtue and
Vidal-Puig, 2010). We showed that the VEGF-induced vessel
density increase in the adipose led to the reversal of metabolic
morbidities caused by HFD. In these mice, decreased levels of
hypoxia and fat inflammation and reduction of adipocyte
size were accompanied by the restoration of normal adipose
function.
A number of recent publications have investigated the role of
VEGF in physiological processes including adipose function
(Elias et al., 2012; Lu et al., 2012; Sun et al., 2012). In addition,
another member of VEGF family, VEGF-B, has also been shown
to regulate lipid transportation and insulin resistance (Hagberg
et al., 2010, 2012). These studies, along with our data, highlight
the unexpected roles of angiogenic growth factors in whole-
body metabolism and unveiled their therapeutic potential for
the treatment of metabolic disease and diabetes (Carmeliet
et al., 2012).
In light of both our LOF and GOF findings, it is intriguing and
seemingly contradictory that a number of preclinical studies
have shown metabolic improvement after treatment with anti-
angiogenic agents (Gregor and Hotamisligil, 2007; Houstis
et al., 2006; Sun et al., 2012). We believe that a significant
part of this discrepancy arises from the systemic nature of
inhibition modalities, which could affect metabolically impor-
tant nonadipose tissues such as liver, skeletal muscle, and
heart as well as energy expenditure and the hypothalamic
appetite control (Bra˚kenhielm et al., 2004; Gaemers et al.,
2011; Liu et al., 2010; Virtue and Vidal-Puig, 2010). These
systemic effects (Lu et al., 2012) may create unknown influ-
ences on whole-body metabolism either directly or indirectly
by stimulating other angiogenic growth factors such as
VEGF-B, which regulate transendothelial fatty acid transporta-
tion in metabolically active organs (Hagberg et al., 2010,
2012). These notions further emphasize the necessity of
models with adipose-specific VEGF deficiency, like the one re-
ported here.
Another reason could be the fact that systemic antiangiogenic
therapies were applied on animals that were already obese
(Houstis et al., 2006; Ozcan et al., 2004; Sun et al., 2012). In
our LOF study, however, angiogenesis was reduced in normal
adipose tissue. It is possible that in obese individuals, the anti-
angiogenic treatment of severely hypoxic adipose tissues
ablates a large proportion of the failing adipocytes, which gives
space for a healthier, less hypoxic regeneration of the adipose
tissue.
Regarding our GOF studies, metabolic protection by in-
creased adipose VEGF expression (started prior to HFD feeding)
has been already demonstrated (Elias et al., 2012; Sun et al.,
2012). Here we stepped further and asked if adipose VEGF acti-
vation (started at the time, when HFD already established meta-
bolic anomaly) could reverse the disease. We found that the
increased blood vessel density achieved by VEGF induction in70 Cell Metabolism 17, 61–72, January 8, 2013 ª2013 Elsevier Inc.deteriorating fat improves adipose function by increasing blood
perfusion, decreasing adipocyte size, reducing hypoxia, and
thereby preventing adipocyte apoptosis or necrosis. These find-
ings led to the important notion that obese adipose failure is
reversible, mediated by sufficient vessel density determined by
VEGF expression. Adipose-VEGF induction reverts the conse-
quence of a cascade of events: adipose hypoxia, adipocyte
apoptosis, adipose inflammation, ectopic lipid deposition, and
lipotoxicity in metabolically compromised animals, and restores
normal glucose homeostasis.
The possibility of adipose-specific modulation of VEGF
signaling opens up novel therapeutic avenues to treat type 2
diabetes and the current epidemic of obesity-related metabolic
diseases.
EXPERIMENTAL PROCEDURES
Animal Maintenance and Studies
All animal care and experimental procedures were approved by the Animal
Care Committees of the Toronto Centre for Phenogenomic (TCP). The colony
was housed in a specific pathogen-free (SPF) facility in ventilated cages with
controlled environment settings (70F–72F, 30%–60% humidity), 12 hr light
and dark cycles, and ad libitum access to water and food (see the Supple-
mental Information for more information).
Histologic and Morphometric Analysis
Mouse tissues were prefixed by perfusion with 1% paraformaldehyde in PBS.
WATs were harvested and used as whole mount, while other tissues, including
liver and brown adipose tissue after postfixation with 4% paraformaldehyde,
were embedded in paraffin for sections and hematoxylin and eosin staining
(see the Supplemental Information for more information).
Statistical Analyses
All calculations were performed using PRISM 5.0C software (GraphPad, San
Diego, CA, USA) and Microsoft Excel 2011 for Mac. Statistical significance
between two groups was determined by the Student’s t test using Microsoft
Excel and PRISM 5.0C. All data are presented as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and one table and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2012.12.010.
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